Is the combinational administration of doxorubicin and glutathione a reasonable proposal?
Authors:
- 14 September 2018
- journal article
- research article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 40 (5) , 699-709
Abstract
The combinational administration of antioxidants and chemotherapeutic agents during conventional cancer treatment is among one of the most controversial areas in oncology. Although the data on the combinational usage of doxorubicin (DOX) and glutathione (GSH) agents have been explored for over 20 years, the duration, administration route, and authentic rationality have not yet been fully understood yet. In the current study, we systematically investigated the pharmacokinetics (PK) and pharmacodynamics (PD) with both in vivo and in vitro models to elucidate the influence of GSH on the toxicity and efficacy of DOX. We first studied the cardioprotective and hepatoprotective effects of GSH in Balb/c mice, H9c2, and HL7702 cells. We showed that coadministration of exogenous GSH (5, 50, and 500 mg/kg per day, intragastric) significantly attenuated DOX-induced cardiotoxicity and hepatotoxicity by increasing intracellular GSH levels, whereas the elevated GSH concentrations did not affect the exposure of DOX in mouse heart and liver. From PK and PD perspectives, then the influences of GSH on the chemotherapeutic efficacy of DOX were investigated in xenografted nude mice and cancer cell models, including MCF-7, HepG2, and Caco-2 cells, which revealed that administration of exogenous GSH dose-dependently attenuated the anticancer efficacy of DOX in vivo and in vitro, although the elevated GSH levels neither influenced the concentration of DOX in tumors in vivo, nor the uptake of DOX in MCF-7 tumor cells in vitro. Based on the results we suggest that the combined administration of GSH and DOX should be contraindicated during chemotherapy unless DOX has caused serious hepatotoxicity and cardiotoxicity.Keywords
This publication has 41 references indexed in Scilit:
- Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stressJournal of Translational Medicine, 2012
- Effect of Vitamin C on Lipidperoxidation and Antioxidant Status in Tamoxifen-Treated Breast Cancer PatientsChemotherapy, 2010
- The Antioxidant DebateEXPLORE, 2010
- Impact of antioxidant supplementation on chemotherapeutic efficacy: A systematic review of the evidence from randomized controlled trialsCancer Treatment Reviews, 2007
- Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutritionBritish Journal of Cancer, 2006
- Doxorubicin hepatotoxicity and hepatic free radical metabolism in ratsToxicology, 2005
- Cardiovascular Complications of Cancer TherapyCirculation, 2004
- Suppression of GST-P by treatment with glutathione-doxorubicin conjugate induces potent apoptosis in rat hepatoma cellsInternational Journal of Cancer, 2001
- Effect of Adriamycin on the Activities of Superoxide Dismutase, Glutathione Peroxidase and Catalase in Tissues of MiceJapanese Journal of Cancer Research, 1989
- Mechanism of adriamycin cardiotoxicity: Evidence for oxidative stressLife Sciences, 1981